Levonorgestrel Patent Expiration
Levonorgestrel is Used for preventing pregnancy with the intrauterine system (IUS). It was first introduced by Population Council
Levonorgestrel Patents
Given below is the list of patents protecting Levonorgestrel, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Liletta | US11571328 | IUD insertion devices | Sep 07, 2040 | Medicines360 |
| Liletta | US10028858 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor | Mar 22, 2034 | Medicines360 |
| Liletta | US11090186 | Methods for using intrauterine systems and IUD insertion devices | Oct 24, 2033 | Medicines360 |
| Liletta | US12004992 | Kits for intrauterine systems and IUD insertion devices | Oct 06, 2033 | Medicines360 |
| Kyleena | US10987244 | Inserter | Apr 01, 2031 | Bayer Hlthcare |
| Kyleena | US9668912 | Inserter | Apr 01, 2031 | Bayer Hlthcare |
| Mirena | US10987244 | Inserter | Apr 01, 2031 | Bayer Hlthcare |
| Mirena | US9668912 | Inserter | Apr 01, 2031 | Bayer Hlthcare |
| Skyla | US10987244 | Inserter | Apr 01, 2031 | Bayer Hlthcare |
| Skyla | US9668912 | Inserter | Apr 01, 2031 | Bayer Hlthcare |
| Kyleena | US10561524 | Inserter | Sep 16, 2029 | Bayer Hlthcare |
| Kyleena | US9615965 | Inserter | Sep 16, 2029 | Bayer Hlthcare |
| Mirena | US10561524 | Inserter | Sep 16, 2029 | Bayer Hlthcare |
| Mirena | US9615965 | Inserter | Sep 16, 2029 | Bayer Hlthcare |
| Skyla | US10561524 | Inserter | Sep 16, 2029 | Bayer Hlthcare |
| Skyla | US9615965 | Inserter | Sep 16, 2029 | Bayer Hlthcare |
| Kyleena | US11850182 | Inserter | Sep 14, 2029 | Bayer Hlthcare |
| Mirena | US11850182 | Inserter | Sep 14, 2029 | Bayer Hlthcare |
| Skyla | US11850182 | Inserter | Sep 14, 2029 | Bayer Hlthcare |
| Kyleena | US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection | Feb 07, 2027 | Bayer Hlthcare |
| Skyla | US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection | Feb 07, 2027 | Bayer Hlthcare |
| Kyleena | US7252839 | Delivery system and a manufacturing process of a delivery system |
Nov 13, 2023
(Expired) | Bayer Hlthcare |
| Skyla | US7252839 | Delivery system and a manufacturing process of a delivery system |
Nov 13, 2023
(Expired) | Bayer Hlthcare |
| Mirena | US5785053 | Inserter for the positioning of an intrauterine device |
Dec 05, 2015
(Expired) | Bayer Hlthcare |
| Skyla | US5785053 | Inserter for the positioning of an intrauterine device |
Dec 05, 2015
(Expired) | Bayer Hlthcare |
Levonorgestrel's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Levonorgestrel:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Tongji Hospital | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | The Methodist Hospital Research Institute | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Efficacy, Safety, and Tolerability of Levonorgestrel Vaginal System | Chemo Research | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia | Xiaojun Chen | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles | Chemo Research | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |